ABSTRACT
PURPOSE: Because the currently available questionnaires to evaluate sexual changes on breast cancer women only address the sexual sphere with a few questions our purpose was to develop a questionnaire that assesses changes in sexual dysfunction and satisfaction in women treated for breast cancer. METHODS: A sample was selected of women aged between 18 and 65 who had had surgery for breast cancer, completed neoadjuvant/adjuvant chemotherapy treatment and could be receiving adjuvant hormonal treatment, with an active sex life at least 3 months before starting treatment. Metastatic disease was excluded. A questionnaire structured in 4 dimensions was developed. The MOS SF-12 and QLQ-BR23 questionnaires were also provided. The following metric properties were evaluated: item analysis; internal consistency; temporal stability; construct validity; concurrent, convergent and divergent validity; and feasibility. RESULTS: Three samples were recruited: a pilot sample of 20; a reduction sample of 152; and a validation sample of 148. The presence of 6 dimensions was confirmed: 1) Loss of sex drive; 2) worsening of body image; 3) psychological coping; 4) discomfort during intercourse; 5) satisfaction with sexual relations; and 6) satisfaction with breast reconstruction. Good goodness-of-fit statistics were obtained (χ2/df = 1.5, GFI = 0.9, AGFI = 0.84, CFI = 0.959, RMSEA = 0.062). Reliability was good (α = 0.855), as was test-retest stability (r = 0.838). The correlation with the convergent questionnaires proved to be higher than that obtained with generic measurements. CONCLUSIONS: We were able to develop a short questionnaire (17 items) capable of measuring sexual satisfaction in women with breast cancer with good metric properties.
Subject(s)
Breast Neoplasms/psychology , Orgasm , Quality of Life , Surveys and Questionnaires/standards , Adaptation, Psychological , Adult , Aged , Body Image/psychology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Reproducibility of ResultsABSTRACT
This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse. Patients with GB at first relapse received TMZ 50 mg/m/2day divided into three doses, except for a single 100 mg/m2 dose, administered between 3 and 6 h before every irinotecan infusion. Irinotecan was given intravenously at the previously established dose of 100 mg/m2 on days 8 and 22 of 28-day cycles. Treatment was given for a maximum of nine cycles or until progression or unacceptable toxicity occurred. Vascular endothelial growth factor and its soluble receptor 1, thrombospondin-1, microparticles, and microparticle-dependent procoagulant activity were measured in blood before treatment. The primary objective was 6-month progression-free survival (PFS). Twenty-seven evaluable patients were enrolled. Six-month PFS was 20.8%. Median PFS was 11.6 weeks (95% confidence interval: 7.5-15.7). Stable disease was the best response for nine (37.5%) patients, with a median duration of 11.2 weeks (4.2-35.85 weeks). No differences in PFS or response were observed among patients who relapsed during or after completion of adjuvant TMZ. Grade 3/4 adverse events included lymphopenia (15%), fatigue, diarrhea and febrile neutropenia (3.7% each), lymphopenia, neutropenia, and nausea/vomiting (11.1% each). One patient died from pneumonia and one patient died from pulmonary thromboembolism. Pretreatment levels of angiogenesis biomarkers, microparticles, and microparticle-related procoagulant activity were elevated in patients compared with healthy volunteers. This regimen is feasible, but failed to improve the results obtained with other second-line therapies in recurrent GB.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/drug therapy , Glioblastoma/drug therapy , Administration, Metronomic , Adult , Aged , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Dacarbazine/administration & dosage , Dacarbazine/analogs & derivatives , Female , Humans , Irinotecan , Male , Middle Aged , Neoplasm Recurrence, Local , TemozolomideABSTRACT
INTRODUCTION: To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure. MATERIALS AND METHOD: The serum levels of endostatin, VEGF and bFGF were determined in postmenopausal patients with progressing MBC from serum samples obtained before initiation of letrozole. The relation between serum angiogenic factor levels and TTP was investigated. RESULTS: Seventy-six patients (45.2%) presented a high endostatin level (> 24.6 ng/ml), 40% low bFGF levels (0 pg/ml) and 50.4% low VEGF (=/< 187 ng/ml). With a median follow-up of 22 months, the median TTP was 12.3 months. Median TTP was worse in patients with high endostatin concentration as well as in the low bFGF group, but was not affected when VEGF was considered. When the two factors were combined, the median TTP of patients with endostatin > 24.6 ng/ml and bFGF equal 0 pg/ml was 9.5 months versus 19.5 months in patients with endostatin =/< 24.6 ng/ml and bFGF > 0 pg/ml. CONCLUSIONS: The baseline levels of bFGF and endostatin are predictive factors of efficacy in patients with MBC treated with letrozole and can select groups with different TTP.
Subject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/blood , Breast Neoplasms/drug therapy , Endostatins/blood , Fibroblast Growth Factor 2/blood , Nitriles/therapeutic use , Triazoles/therapeutic use , Adult , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Breast Neoplasms, Male/blood , Breast Neoplasms, Male/drug therapy , Breast Neoplasms, Male/pathology , Disease Progression , Female , Humans , Letrozole , Male , Middle Aged , Predictive Value of Tests , Prospective StudiesABSTRACT
Introduction. To investigate the value of baselineserum levels of VEGF, bFGF, endostatin and theirratio as predictive factors of response to endocrinetherapy in patients with metastatic breast cancer(MBC) and positive ER treated with letrozole aftertamoxifen failure.Materials and method. The serum levels of endostatin,VEGF and bFGF were determined in postmenopausalpatients with progressing MBC fromserum samples obtained before initiation of letrozole.The relation between serum angiogenic factorlevels and TTP was investigated.Results. Seventy-six patients (45.2%) presented ahigh endostatin level (> 24.6 ng/ml), 40% low bFGFlevels (0 pg/ml) and 50.4% low VEGF ( 24.6 ng/ml and bFGF equal 0 pg/mlwas 9.5 months versus 19.5 months in patients withendostatin 0 pg/ml.Conclusions. The baseline levels of bFGF and endostatinare predictive factors of efficacy in patientswith MBC treated with letrozole and can selectgroups with different TTP
No disponible
